Scheduled Maintenance
We have scheduled some maintenance on Saturday 4th of May 2024 starting from 10AM CEST and could last for 2 hours. During this maintenance we are expecting our website to be unavailable or not fully functional.
HEPION PHARMACEUTICALS INC (HEPA)
US4268973025 - Common Stock
HEPION PHARMACEUTICALS INC
NASDAQ:HEPA (5/3/2024, 7:00:01 PM)
1.46
-0.06 (-3.95%)
Company Profile
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. The company is headquartered in Edison, New Jersey and currently employs 25 full-time employees. The company went IPO on 2014-02-07. The firm is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The firm's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Company’s rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The firm provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.
Company Info
HEPION PHARMACEUTICALS INC
399 Thornall St
Edison NEW JERSEY 08837
P: 17329024000
CEO: Robert Foster
Employees: 25
Website: https://hepionpharma.com/
HEPA News
Friday, Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) said it has begun winding down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as announced in December 2023. ASCEND-NASH is a Phase 2b, randomized, multicenter, double-blinded study with the first patient screened in August 2022 to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enrollment was paused in April 2023, with 151 subjects randomized
12 days ago - InvestorPlaceNike Layoffs 2024: What to Know About the Latest Nike Job CutsNike layoffs are on the way as the athletic wear company is preparing to cut 740 jobs in two rounds at its global headquarters.
12 days ago - InvestorPlaceWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?Hepion Pharmaceuticals stock is falling on Monday as investors in HEPA learn of the company winding down a Phase 2b clinical trial.
12 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start ofd the trading week with a look at the biggest pre-market stock movers traders need to watch on Monday morning!
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been...
17 days ago - InvestorPlaceHEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023HEPA stock results show that Hepion Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
HEPA Twits
Here you can normally see the latest stock twits on HEPA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
